purpose work investigate efficacy radioimmunotherapy using fab2 fab2 nonspecific antibody differently advanced ovarian cancer mice b image tumor growth peritoneum c calculate specific energy mean absorbed dose tumors critical organs methods experiments nude mice n NUMBER NUMBER intraperitoneally inoculated approximately NUMBER x NUMBER cells NUMBER NUMBER NUMBER NUMBER NUMBER wk inoculation animals intraperitoneally treated approximately NUMBER kbq fab2 n NUMBER NUMBER approximately NUMBER kbq fab2 n NUMBER NUMBER unlabeled rituximab fab2 n NUMBER NUMBER time treatment NUMBER animals sacrificed biopsies taken determination tumor sizes using scanning electron microscopy sem weeks treatment animals sacrificed presence microscopic tumors ascites determined specific energy mean absorbed dose tumors calculated activity concentration measured critical organs abdominal fluid results given treatment NUMBER NUMBER NUMBER NUMBER NUMBER wk cell inoculation fraction tff NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER treated fab2 fab2 respectively sem images revealed maximum tumor radius approximately NUMBER mum NUMBER wk cell inoculation increasing approximately NUMBER mum NUMBER wk specific energy cell nuclei varied NUMBER approximately NUMBER gy depending assumptions regarding activity distribution tumor size mean absorbed dose thyroid kidneys bone marrow approximately NUMBER approximately NUMBER approximately NUMBER gy respectively conclusion treatment fab2 fab2 resulted tff tumor radius NUMBER microm tff decreased tff NUMBER fab2 tumor radius exceeded range specific antibody gave tumor sizes significantly better tff explained high mean absorbed dose NUMBER gy activity bound tumor surface probably contribution penetrating activity 211at mx35 211at rituximab NUMBER wk old nihovcar NUMBER 211at mx35 211at rituximab macro tumor free 211at mx35 211at rituximab 211at mx35 211at rituximab NUMBER NUMBER 211at rituximab alpha particles